The Short Overview on the Relevance of Fatty Acids for Human Cardiovascular Disorders
Viktoriya S. Shramko,
Yana V. Polonskaya,
Elena V. Kashtanova,
Ekaterina M. Stakhneva,
Yuliya I. Ragino
Affiliations
Viktoriya S. Shramko
Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Research Institute of Internal and Preventive Medicine, 630089 Novosibirsk, Russia
Yana V. Polonskaya
Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Research Institute of Internal and Preventive Medicine, 630089 Novosibirsk, Russia
Elena V. Kashtanova
Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Research Institute of Internal and Preventive Medicine, 630089 Novosibirsk, Russia
Ekaterina M. Stakhneva
Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Research Institute of Internal and Preventive Medicine, 630089 Novosibirsk, Russia
Yuliya I. Ragino
Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Research Institute of Internal and Preventive Medicine, 630089 Novosibirsk, Russia
This review presents existing evidence of the influence of saturated and unsaturated fatty acids on cardiovascular diseases (CVD). Data are discussed regarding the roles of the most relevant fatty acids, such as myristic (C14:0), palmitic (C16:0), stearic (C18:0), palmitoleic (C16:1), oleic (C18:1), linoleic (C18:2), α-linolenic (C18:3, ω-3), γ-linolenic (C18:3, ω-6), arachidonic (C20:4), eicosapentaenoic (C20:5), docosahexaenoic (C22:6), and docosapentaenoic (C22:5) acid. The accumulated knowledge has expanded the understanding of the involvement of fatty acids in metabolic processes, thereby enabling the transition from basic exploratory studies to practical issues of application of these biomolecules to CVD treatment. In the future, these findings are expected to facilitate the interpretation and prognosis of changes in metabolic lipid aberrations in CVD.
